Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?

Diabetes care

Volumn 31 Suppl 2, Issue , 2008, Pages

  Stirban, Alin O ^a   Tschoepe, Diethelm ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DRUG COMBINATION; HUMAN; PRIMARY PREVENTION;

ASPIRIN; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION;

MLCS; MLOWN;

EID: 41149161578     PISSN: None     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-s254     Document Type: Article

References (0)